推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

ANTI-CANCER DRUGS 期刊收藏夹

欢迎您加入月均活跃用户100万+的科研社区!如您有任何系统建议,请点此反馈;如有合作推广需求,请点此洽谈

按期刊名首写字母查看 ANTI-CANCER DRU最新评论:我看很多人都是当天接收的 (2025-04-04)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:
近期推荐:
SCI论文AI润色+人工QC服务
同行专家帮助选刊
Springer Nature特刊征稿
同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


ANTI-CANCER DRUGS期刊基本信息Hello,您是该期刊的第59240位访客


基本信息 登录收藏
期刊名字ANTI-CANCER DRUGSANTI-CANCER DRUGS

ANTI-CANCER DRUG
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
5.7
55人评分
我要评分

声誉
6.5

影响力
4.4

速度
8.7

期刊ISSN0959-4973
蝌蝌APP,让您与同行交流更轻松
立即下载
E-ISSN1473-5741
2024-2025最新影响因子
(数据来源于搜索引擎)
2.2 点击查看影响因子趋势图
实时影响因子 截止2025年5月19日:2.136
2024-2025自引率4.50%点击查看自引率趋势图
五年影响因子1.9
JCI期刊引文指标 0.61
h-index 88
CiteScore
2025年最新版
CiteScoreSJRSNIPCiteScore排名
4.100.5320.421
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q2127 / 275
大类:Medicine
小类:Oncology
Q2199 / 415
大类:Medicine
小类:Pharmacology
Q3177 / 321
大类:Medicine
小类:Cancer Research
Q3148 / 233

期刊简介
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
期刊官方网站http://journals.lww.com/anti-cancerdrugs/pages/default.aspx
期刊投稿格式模板
VIP专享
Word版格式模板  
此模板由LetPub整理,仅供参考。开通VIP可免费下载,并享1w+期刊模板资源。
 
期刊投稿网址https://www.editorialmanager.com/ACD
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足ANTI-CANCER DRUGS的语言要求,还能让ANTI-CANCER DRUGS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被ANTI-CANCER DRUGS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(2篇)
提交文稿
是否OA开放访问No
通讯方式LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621
出版商Lippincott Williams and Wilkins Ltd.
涉及的研究方向医学-药学
出版国家或地区UNITED STATES
出版语言English
出版周期Monthly
出版年份1990
年文章数 121点击查看年文章数趋势图
Gold OA文章占比21.23%
研究类文章占比:
文章 ÷(文章 + 综述)
96.69%
WOS期刊SCI分区
2024-2025年最新版
WOS分区等级:3区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ3216/326
学科:PHARMACOLOGY & PHARMACYSCIEQ3209/352
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ3180/326
学科:PHARMACOLOGY & PHARMACYSCIEQ3198/353
中国科学院《国际期刊预警
名单(试行)》名单
2025年03月发布的2025版:不在预警名单中

2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2025年3月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区4区2区
ONCOLOGY
肿瘤学
1区3区4区
PHARMACOLOGY & PHARMACY
药学
4区2区4区
中国科学院SCI期刊分区
2023年12月升级版
大类学科小类学科Top期刊综述期刊
医学 4区4区4区
ONCOLOGY
肿瘤学
1区1区4区
PHARMACOLOGY & PHARMACY
药学
4区1区4区
中国科学院SCI期刊分区
2022年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 3区4区3区
ONCOLOGY
肿瘤学
3区1区4区
PHARMACOLOGY & PHARMACY
药学
4区2区4区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0959-4973%5BISSN%5D
平均审稿速度网友分享经验:
偏慢,4-8周
平均录用比例网友分享经验:
容易
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在ANTI-CANCER DRUGS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(2篇)
提交文稿
期刊常用信息链接
同领域相关期刊 ANTI-CANCER DRUGS期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 ANTI-CANCER DRUGS中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
ANTI-CANCER DRUGS上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    DRUG RESISTANCE UPDATES10023.20
    TRENDS IN PHARMACOLOGICAL SCIENCES20125.70
    ADVANCED DRUG DELIVERY REVIEWS27836.00
    PHARMACOLOGICAL REVIEWS21034.00
    PHARMACOLOGY & THERAPEUTICS18026.20
    MEDICINAL RESEARCH REVIEWS11929.50
    PHARMACOLOGICAL RESEARCH11818.60
    PHYTOMEDICINE10511.60
    DRUG DELIVERY5216.40
    BRITISH JOURNAL OF PHARMACOLOGY19014.40
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE744587
    BIOMATERIALS616539
    BIOMEDICINE & PHARMACOTHERAPY609760
    Frontiers in Pharmacology576582
    COMPUTERS IN BIOLOGY AND MEDICINE574044
    JOURNAL OF ETHNOPHARMACOLOGY570356
    Frontiers in Immunology564645
    Frontiers in Oncology505669
    COLLOIDS AND SURFACES B-BIOINTERFACES472331
    PHYTOMEDICINE470989
  •  

    ANTI-CANCER DRUGS ANTI-CANCER DRUGS
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Iruplinalkib for G1202R-mutant non-small cell lung cancer with anaplastic lymphoma kinase double fusion failed to alectinib: a case report

    Author: Yang, Guangjian; Hu, Jiaqi; Liu, Runze; Li, Pei; Yang, Linke; Tang, Xiaoyong; Wang, Luokun
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 432-437. DOI: 10.1097/CAD.0000000000001695
        PubMed      DOI
    2.Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature

    Author: Yang, Can; Zhang, Cui; Huang, Yisidan; Zhu, Xiong; Jiang, Jia; Zeng, Yuting; Zhang, Hanqun; Li, Libo; Liu, Yuncong; Li, Yong
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. -. DOI: 10.1097/CAD.0000000000001702
        PubMed      DOI
    3.Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study

    Author: Xu, Chang; Ren, Jing; Liu, Changqing; Gai, Yi; Cheng, Xiangyu; Wang, Yusheng; Wang, Guangyu
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 383-393. DOI: 10.1097/CAD.0000000000001697
        PubMed      DOI
    4.Combined protein and transcriptomics identifies DCTPP1 as a putative biomarkers for predicting immunotherapy responsiveness in gastric cancer patients

    Author: Wei, Jun; Qin, Yuexuan; Zhang, Luwen; Gong, Xiaobing
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 415-426. DOI: 10.1097/CAD.0000000000001704
        PubMed      DOI
    5.Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment

    Author: Tan, Tingfei; Yuan, Siyu; Chu, Weiwei; Jiang, Jiemei; Chen, Meiling; Xia, Quan; Wang, Junping
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 408-414. DOI: 10.1097/CAD.0000000000001701
        PubMed      DOI
    6.Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years

    Author: Su, Wenzhong; Li, Jianqiang
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 401-407. DOI: 10.1097/CAD.0000000000001699
        PubMed      DOI
    7.A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer

    Author: Li, Siyuan; Zhang, Yanqin; Yang, Rong; Yang, Qingfan; Han, Shuangyan; Li, Dan; Zhang, Zhenhua; Wen, Qinglian
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 394-400. DOI: 10.1097/CAD.0000000000001698
        PubMed      DOI
    8.BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells

    Author: Jia, Zhu-xia; Xiao, Bi-tao; Li, Jin; Cai, Xiao-hui; Qin, Wei; Zhou, Min; Lu, Xu-zhang
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 374-382. DOI: 10.1097/CAD.0000000000001696
        PubMed      DOI
    9.Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report

    Author: Guo, Yanrong; Zhai, Jinfang; Yang, Yanli; Wei, Qin; Li, Shengshu; Huo, Rujie; Tong, Guoping; Xu, Enwei; Chen, Yan; Han, Songyan; Chen, Deyi
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 427-431. DOI: 10.1097/CAD.0000000000001693
        PubMed      DOI
    10.BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK/ERK pathway

    Author: Deng, Yingcheng; Li, Yilin; Cao, Hong
    Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 5, pp. 359-373. DOI: 10.1097/CAD.0000000000001694
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS1441154.20
    NATURE REVIEWS DRUG DISCOVERY289181.80
    Kidney International Supplements2046.20
    Kidney International Supplements2446.20
    LANCET70087.60
    Nature Reviews Clinical Oncology127114.50
    NEW ENGLAND JOURNAL OF MEDICINE93396.40
    NATURE REVIEWS CANCER396103.80
    World Psychiatry6174.00
    World Psychiatry7074.00
    同分区等级的其他期刊名称 h-index CiteScore
    Corrosion Communications013.60
    Water Cycle09.60
    Journal of Road Engineering010.30
    Ukrainian Journal of Physical Optics1412.30
    Integrated Environmental Assessment and Management486.90
    Progress of Theoretical and Experimental Physics3110.40
    Journal of Obesity & Metabolic Syndrome011.10
    HARVARD BUSINESS REVIEW01.80
    PUBLICATIONS OF THE ASTRONOMICAL SOCIETY OF THE PACIFIC1367.90
    Pulse00.00
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

同领域作者分享投稿经验:共185


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2025 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室